×

Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial

By Thomson Reuters Nov 20, 2026 | 6:39 AM

Nov 20 (Reuters) – Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal ​cancers live longer than standard treatment ‌options in a late-stage trial.

Here are some details:

• The trial compared the drug, sacituzumab tirumotecan, also known as sac-TMT, to physician-selected chemotherapy, including trifluridine-tipiracil, ‌irinotecan, ​paclitaxel or docetaxel

• The ⁠trial enrolled 473 ⁠patients whose cancer could not be removed by surgery and whose disease had progressed after at least two earlier treatments

• Sac-TMT ​is an antibody-drug conjugate, a type of targeted cancer therapy designed to ⁠deliver cancer-killing drugs directly ⁠to tumor cells while minimizing damage ​to healthy tissue

• Merck said sac-TMT met ​the trial’s main goal of improving overall ‌survival but did not disclose detailed data, which it plans to present at a future medical meeting

• The study, however, did ⁠not meet its secondary goal of delaying cancer progression, as measured by an independent review. Merck ⁠said the ‌drug had no new safety ⁠concerns

• The results mark another ​positive ‌late-stage trial for sac-TMT, which ​Merck licensed ⁠from China’s Kelun-Biotech for markets outside Greater China

• Merck is currently testing sac-TMT for multiple cancers, including lung, breast and gastrointestinal tumors

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by ​Aseem Gujar)